Summary
- TransMedics has filed to raise $86.25 million in an IPO, although the final figure may be different.
- The company is commercializing an organ transplant care system in the U.S.
- TMDX has grown topline revenue and gross profit from a small base but is burning through cash.
- This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today ยป
Quick Take
TransMedics Group (TMDX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm has developed the Organ Care System [OCS], a portable device that maintains donor organs in a human-like state.
TMDX is growing revenue and gross profit from a small base but needs additional funding for working capital and further development purposes.
